DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.
|Number of pages||6|
|Journal||British Journal of Diabetes and Vascular Disease|
|Publication status||Published - 1 May 2007|
- Type 2 diabetes